Novo Nordisk Inc Company Profile

What is the competitive landscape for NOVO NORDISK INC

NOVO NORDISK INC has four approved drugs.

There are two US patents protecting NOVO NORDISK INC drugs.

Summary for Novo Nordisk Inc

US Patents:	2
Tradenames:	4
Ingredients:	3
NDAs:	4
Patent Litigation for Novo Nordisk Inc:	See patent lawsuits for Novo Nordisk Inc

Drugs and US Patents for Novo Nordisk Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes	9,968,659*PED				Y
Novo Nordisk Inc	INNOFEM	estradiol	TABLET;ORAL	040312-003	Nov 19, 1999		DISCN	No	No
Novo Nordisk Inc	PRANDIMET	metformin hydrochloride; repaglinide	TABLET;ORAL	022386-001	Jun 23, 2008		DISCN	Yes	No
Novo Nordisk Inc	VAGIFEM	estradiol	TABLET;VAGINAL	020908-002	Nov 25, 2009	AB	RX	Yes	Yes
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes	8,114,833*PED				Y
Novo Nordisk Inc	PRANDIMET	metformin hydrochloride; repaglinide	TABLET;ORAL	022386-002	Jun 23, 2008		DISCN	Yes	No
Novo Nordisk Inc	INNOFEM	estradiol	TABLET;ORAL	040312-002	Nov 19, 1999		DISCN	No	No

Expired US Patents for Novo Nordisk Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo Nordisk Inc	PRANDIMET	metformin hydrochloride; repaglinide	TABLET;ORAL	022386-002	Jun 23, 2008	RE37035
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	6,004,297
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	7,235,627
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	6,458,924
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	RE43834
Novo Nordisk Inc	PRANDIMET	metformin hydrochloride; repaglinide	TABLET;ORAL	022386-002	Jun 23, 2008	6,677,358
Novo Nordisk Inc	PRANDIMET	metformin hydrochloride; repaglinide	TABLET;ORAL	022386-001	Jun 23, 2008	6,677,358

Paragraph IV (Patent) Challenges for NOVO NORDISK INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	18 mg/3 mL prefilled syringe		2016-12-12
	Vaginal Tablets	10 mcg		2013-01-02
	Tablets	1 mg/500 mg and 2 mg/500 mg		2009-04-09

International Patents for Novo Nordisk Inc Drugs

Country	Patent Number	Estimated Expiration
Spain	2727854
South Korea	20180114168
Spain	2660320
South Korea	20060100428
Slovenia	3300721
Japan	2007513084
Croatia	P20211492

Supplementary Protection Certificates for Novo Nordisk Inc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	C300677	Netherlands		PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
2498758	2020C/509	Belgium		PRODUCT NAME: QTRILMET - METFORMINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; SAXAGLIPTINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; DAPAGLIFLOZINE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1401 20191113
1506211	C01506211/02	Switzerland		PRODUCT NAME: DAPAGLIFLOZIN + METFORMIN; REGISTRATION NO/DATE: SWISSMEDIC 65377 16.07.2015
2782584	21C1058	France		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406
1532149	CA 2013 00001	Denmark		PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION ENANTIOMERER OG SALTE DERAF - SAERLIGT LINAGLIPTIN - I KOMBINATION MED METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/12/780/001-028 20120720
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1380301	CA 2009 00017	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Novo
• Novo Nordisk
• Novo Nordisk Inc

Executive summary
Novo Nordisk Inc. holds a top tier position in global diabetes and obesity markets, supported by a dense IP moat around GLP-1 and GLP-1/GIP platforms, multi-year clinical differentiation, and a vertically integrated manufacturing footprint that reduces supply-risk for high-demand injectables. Its near-term competitive pressure comes from (1) incretin rivals expanding across cardiometabolic endpoints, (2) biosimilar/generic substitution risk that is structurally lower for injectable peptide biologics but rising for specific “adjacent” products and devices, and (3) payer and HTA cost-containment that accelerates faster switching to lower-cost options when exclusivity narrows. The strategic pattern that has mattered most is the sequencing of line extensions, fixed-dose combinations, and device-led adoption to extend effective exclusivity beyond first-label patent expiry.

What is Novo Nordisk’s market position in diabetes and obesity versus competitors?

Novo Nordisk is the category leader in GLP-1–based therapies for type 2 diabetes (T2D) and obesity, with an incumbent portfolio that spans:

• GLP-1 receptor agonists (injectable peptides)
• GLP-1/GIP dual agonists
• Fixed-dose and titration-optimized regimens
• Cardiometabolic outcome labels and obesity disease progression claims (where approved)

How does Novo Nordisk rank by commercial footprint?

Novo Nordisk’s competitive edge is less about a single asset and more about breadth across:

• Indication coverage (T2D, weight management, and comorbidity-linked labels)
• Line-of-therapy coverage (early intensification versus later escalation)
• Formulation and delivery formats (pen devices, dose flexibility, and titration design)
• Supply scale (large-scale peptide manufacturing and fill-finish execution)

Which competitors pressure Novo Nordisk the most?

The competitive set is dominated by incretin and cardiometabolic franchises:

• Eli Lilly (GLP-1 and dual agonist portfolio)
• Amgen (obesity and metabolic pipeline focus)
• AstraZeneca (metabolic and diabetes assets and obesity-adjacent development)
• Sanofi (diabetes portfolio with GLP-1 exposure through development partnerships)
• Biotech and specialty players pursuing next-gen incretin schedules, oral peptides, or receptor-selective approaches

How strong is Novo Nordisk’s IP moat versus incretin rivals?

Novo Nordisk’s patent posture typically covers:

• Active ingredient composition and analog variants (compound claims)
• Pharmaceutical compositions and formulation/particle-structure claims
• Device and administration regimen claims (where supported)
• Method-of-use claims tied to specific dosing, titration, and clinical outcomes
• Manufacturing/process claims for peptide synthesis and purification

The practical impact is that competitors face overlapping litigation and “design-around” risk when they attempt to launch:

• The same peptide backbone
• Similar dose regimens
• Comparable formulations
• Substitution at the level of method-of-use (where patent coverage is broad)

How strong is the patent estate for Novo Nordisk’s key products?

Novo Nordisk’s strength is anchored in multi-layer protection around its best-selling incretin molecules, usually spanning:

• Composition-of-matter
• Pharmaceutical composition and stability
• Dosing regimen and method-of-use
• Manufacturing and impurity profiles
• Country-by-country enforceability

What kinds of patents protect Novo Nordisk injectable peptides?

Typical claim coverage categories for injectable peptide franchises:

• “Compound” claims: peptide sequences, substitutions, stereochemistry
• “Formulation” claims: buffers, stabilizers, pH windows, concentration ranges, isotonicity, and reconstitution requirements
• “Method-of-use” claims: dosing schedules, titration steps, response-based escalations
• “Process” claims: synthesis routes, purification methods, crystallization conditions, and control of critical impurities
• “Device” claims: pen mechanics and dosing system claims where patentable subject matter exists

How many patent layers drive long-tail exclusivity?

In practice, long-tail exclusivity is created by staggered filings and continuation practice across:

• Multiple jurisdictions
• Multiple therapeutic claims (T2D, obesity, cardiometabolic outcomes)
• Multi-year stability and formulation refinements
• Device updates and manufacturing optimization filings

That layering makes it harder for generic and biosimilar entrants to secure clean legal pathways without addressing multiple independently enforceable claims.

What are the most common litigation and settlement patterns in this space?

For peptide-based injectables:

• Paragraph IV challenges are less relevant when products are regulated as biologics or when composition and method patents are broad and multiple
• Where competitors use biosimilar pathways, litigation centers on similarity and safe use rather than classic generic substitution
• Settlements frequently produce delayed entry at the claim level rather than a single “hard stop,” reflecting the layered estate

When does Novo Nordisk’s exclusivity begin to shrink, and what triggers earlier generic or biosimilar risk?

Exclusivity shrink is driven by:

• Primary compound patent expiry windows
• Extended protection tied to regulatory data and patent term adjustments
• Method-of-use patent expiry schedules
• Formulation patent expiry schedules
• Device and manufacturing patent expiry schedules
• Competitive entry timing tied to launch logistics and label expansions

What timelines determine effective exclusivity in practice?

Effective exclusivity can end later than the first patent expiry when:

• Multiple method-of-use patents remain enforceable
• Formulation or stability patents block AB-type substitution
• Device claims constrain “at-design” entry products
• Settlement agreements add a contractual delay

What triggers faster payer switching once exclusivity loosens?

Payer and HTA behavior becomes decisive when:

• Therapeutic alternatives reach equivalent guideline status
• Price benchmarks shift (WAC, net, and rebates)
• Budget impact models change due to new entrants or oral/superior delivery modalities
• Clinical differentiation narrows on hard outcomes (for example, cardiovascular endpoint evidence)

What formulations are protected by Novo Nordisk, and how do they affect generic entry risk?

Formulation patents matter because they can block biosimilar/generic approvals where regulatory comparability or sameness standards are not met.

What formulation elements are usually patent-protected?

Patent filings often cover:

• Buffer and pH selection
• Stabilizer systems that maintain peptide integrity
• Concentration windows and excipient choices
• Shelf-life and in-use stability parameters
• Pen fill/finish stability and temperature excursions

How do formulation blocks translate into market delay?

If a competitor must choose a meaningfully different composition to avoid infringement, it can face:

• Label and stability differences requiring additional bridging
• Patent “risk” on the method-of-use side if the clinical program is not aligned
• Longer commercialization timelines due to device compatibility and manufacturing scale-up

What method-of-use patents matter most for Novo Nordisk’s clinical claims?

Method-of-use patents can be the most durable layer when they cover:

• Specific dosing titration schedules
• Patient subgroups (based on baseline BMI, diabetes status, or risk profile)
• Combination rules for escalation
• Treatment goals and clinical response thresholds used to define the method

Where do method-of-use patents create practical barriers for entrants?

Entrants can launch “competing” drugs but still face:

• Induced infringement or direct infringement theories tied to prescribed regimens
• Barriers to marketing language that matches protected claims
• Settlement-driven limitations on label scope and patient targeting

Which companies are challenging Novo Nordisk’s dominance through incretin competition?

Eli Lilly

Eli Lilly is the most direct commercial comparator with strong GLP-1 and dual agonist pipeline and label momentum, putting pressure on:

• Payer formularies
• Access negotiations
• Uptake in treatment-naïve and intensification segments

Amgen

Amgen’s competitive posture depends on:

• The magnitude of clinical differentiation on weight and metabolic outcomes
• Manufacturing scale readiness for high-demand schedules
• Contracting and bundle strategies with payers

AstraZeneca and others

Non-core incretin players can pressure demand through:

• Alternative mechanisms that reduce reliance on GLP-1
• Broader metabolic portfolios that support formulary inclusion

What is the Orange Book status of Novo Nordisk products, and what does it imply for generic entry?

Orange Book status is relevant for small-molecule drugs and approved drug products with listed patents. For injectable peptide biologics, the regulatory and patent landscape is often more complex and not purely Orange Book-driven. The key practical implication for market participants is:

• Where a Novo Nordisk product is listed under the Orange Book framework, patent listings can predict the “AB-application risk” window.
• Where biologics or separately regulated products apply, litigation and biosimilar frameworks dominate.

Because a correct product-by-product Orange Book map requires product identifiers and listed patent numbers, no product-level Orange Book status can be asserted here.

What FDA pathway issues affect Novo Nordisk’s competitive pressure and exclusivity durability?

How do FDA designations shape generic/biosimilar risk?

FDA pathway designation affects:

• Availability of abbreviated application pathways
• The evidentiary burden for comparability or sameness
• Labeling and interchangeability constraints
• Timing leverage during litigation

What role do label expansions play?

Label expansion can:

• Extend commercial capture to new patient segments
• Create new method-of-use footprints that overlap existing or new claims
• Alter payer coverage decisions and reduce substitution

How does Novo Nordisk compare with Eli Lilly on IP strength and commercial risk?

Core difference in competitive exposure

Last updated: July 23, 2026

• Both firms rely on incretin platform IP and multi-layer protection.
• The main differentiator is timing of line extensions and breadth of claim coverage across formulations and method-of-use.

Practical competitive outcome

• When two incumbents launch in overlapping windows, each can preserve “effective exclusivity” through different mixes of: next-dose labels, combination products, device updates, and claim-rich method-of-use coverage.

No product-by-product expiration schedule is provided here because it requires specific patent numbers and FDA product identifiers.

What patent litigation affects Novo Nordisk, and how do settlements influence launch timing?

Litigation and settlements in this sector typically:

• Resolve disputes at the claim level through consent judgments or stipulations
• Delay entry rather than invalidate patents outright
• Limit label scope or promotional activities in early launch phases

Market impact mechanics

• A settlement can create a deterministic “delayed entry” date even if a competitor could otherwise launch against fewer claims.
• A competitor may refile or adjust the product dossier to target a different patent subset, changing timing by months to years.

No litigation docket detail can be listed without specific case identifiers, product names, and asserted patents.

What generic entry risks exist for Novo Nordisk’s portfolio, and where is risk highest?

Generic entry risk is not uniform across a peptide-heavy portfolio.

Highest risk zones (in general)

• Products with less layered IP or fewer formulation and method-of-use patents
• Lower-demand SKUs where entry economics favor faster launches
• Segments where alternative delivery formats reduce the need for direct formulation replication

Lowest risk zones (in general)

• Core high-revenue injectables with dense, multi-jurisdictional claim sets
• Products with active method-of-use and stability/formulation constraints
• Highly optimized dosing and device-driven regimens

Which Novo Nordisk manufacturing and IP barriers matter for competitors trying to scale?

Competitive threat is constrained when a firm cannot secure:

• Manufacturing capacity for high purity peptides at scale
• Robust fill-finish and device integration
• Stability-controlled warehousing and cold-chain logistics
• Quality system compliance consistent with FDA expectations

Even when legal barriers weaken, execution barriers can slow entry and limit initial uptake.

Key strategic insights for licensing, litigation, and investment decisions

For licensing

• Prioritize diligence on method-of-use claim scope tied to dosing and outcome endpoints.
• Focus on formulation and stability patent coverage that can force redesign or delay bridging.

For litigation

• Evaluate claim stacking: compound + formulation + method-of-use + process can produce multiple independent infringement theories.
• Settlement value often comes from early-entry windows tied to specific label carve-outs, not only from stopping launch entirely.

For investment and competitive modeling

• Model effective exclusivity with a “claim clock,” not a single patent expiry date.
• Tie payer switching probability to: net price delta, formulary tier status, and clinical differentiation durability.

Key Takeaways

• Novo Nordisk’s market power in diabetes and obesity is driven by portfolio breadth, multi-layer incretin IP, and manufacturing scale that reduces supply and execution risk.
• Competitive pressure is concentrated in GLP-1 and dual agonist franchises, but layered formulation and method-of-use patent estates tend to preserve effective exclusivity.
• The most actionable risk lens is “claim clock” modeling: compound expiry is only one driver; method-of-use and formulation patents plus settlements often determine launch timing.
• Payer and HTA behavior becomes the main lever once alternatives reach guideline-consistent status or when exclusivity loosens unevenly across SKUs.

FAQs

1. How does method-of-use patent coverage influence prescribing and payer formularies for GLP-1 therapies?
2. What manufacturing or device patents most often slow down “at-launch” generic or biosimilar commercialization for peptide injectables?
3. How do label expansions on cardiovascular outcomes change competitive substitution risk in diabetes and obesity?
4. What settlement structures most commonly determine the effective entry date after a patent challenge?
5. Which factors most strongly predict whether competitors can secure access through managed care despite ongoing IP?

References

1. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration.
2. FDA. Biosimilars. U.S. Food and Drug Administration.
3. Novo Nordisk. Annual Reports and SEC filings (latest available). Novo Nordisk A/S.